Arkansas’ lawsuit against Johnson & Johnson for false and misleading claims regarding Risperdal is set to begin today, the fourth time J&J has a faced a state’s complaints about the drug. Arkansas is accusing J&J of hiding the serious health risks of Risperdal, and of promoting it for unapproved uses such as the treatment of dementia and Alzheimer’s disease, despite evidence that the drug increased the risk of death in elderly patients. The minimum penalty of $5,000 per prescription would total an award of $1.25 billion.
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.